25 analysts have shared their evaluations of Regeneron Pharmaceuticals (NASDAQ:REGN) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 17 | 4 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 1 | 0 |
| 2M Ago | 1 | 13 | 2 | 0 | 0 |
| 3M Ago | 2 | 4 | 1 | 0 | 0 |
Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $1086.64, a high estimate of $1300.00, and a low estimate of $165.00. A 10.22% drop is evident in the current average compared to the previous average price target of $1210.38.
Deciphering Analyst Ratings: An In-Depth Analysis
A clear picture of Regeneron...
Login or create a forever free account to read this news
Sign up/Log in
